Robotics AI Scale Vivodyne is expanding with a 23,000-square-foot fully robotic laboratory in South San Francisco funded by a new $40M Series A, highlighting a scalable automation platform and significant capacity growth ideal for partnerships or manufacturing collaborations.

Human Tissue Focus The company accelerates drug discovery using lab-grown human tissues, shifting away from animal models. This presents opportunities to position platform-validated human-relevant data to pharma and biotech firms seeking more predictive preclinical results.

Funding Momentum Recent seed and Series A funding rounds totaling at least $78M, with ongoing investor confidence from Khosla Ventures and others, signaling a robust growth trajectory and potential for co-development or sponsored research programs.

Leadership Signals Key hires in 2024 for COO and CTO roles indicate strong operational and technical governance, suggesting readiness for enterprise partnerships, large-scale pilots, and long-term collaboration with pharma, CROs, and research institutions.

Tech Stack & Data Leveraging robotics, AI, and cloud-based workflows (GCP, Google Workspace, Claude Code) combined with scalable tissue testing positions Vivodyne as a data-rich partner for providers seeking integrated automation, analytics, and high-throughput preclinical services.